{
    "nctId": "NCT02890368",
    "briefTitle": "Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides",
    "officialTitle": "A Phase 1 Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides",
    "overallStatus": "TERMINATED",
    "conditions": "Solid Tumors, Mycosis Fungoides, Melanoma, Merkel-cell Carcinoma, Squamous Cell Carcinoma, Breast Carcinoma, Human Papillomavirus-Related Malignant Neoplasm, Soft Tissue Sarcoma",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 56,
    "primaryOutcomeMeasure": "Optimal TTI-621 delivery regimen",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically documented, injectable cancer lesion (limited to solid tumors and mycosis fungoides)\n* Adequate renal function\n* Adequate coagulation function\n* Adequate hepatic function\n* Disease that has progressed on standard therapy or for whom there is no other therapy option available\n\nExclusion Criteria:\n\n* Central nervous system involvement\n* Significant cardiovascular disease\n* Active autoimmune disease\n* Active hepatitis B or C or a history of HIV infection\n* Uncontrolled infection\n* History of hemolytic anemia or bleeding diathesis",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}